Full text is available at the source.
Abstract
An evaluation of glucagon-like peptide-1 receptor agonists (GLP-1 RA) therapy in chronic pancreatitis was conducted using data from the TriNetX US Collaborative Network.
- The study investigates the potential impacts of GLP-1 RA therapy on pancreatic and gastrointestinal outcomes in patients with chronic pancreatitis.
- It also explores the association of GLP-1 RA therapy with mortality outcomes in this patient population.
- Findings could inform the understanding of GLP-1 RA therapy's role in managing chronic pancreatitis.
Simplified